-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Beyond TTP: “Atypical” TMAs for the Hematologist

Program: Education Program
Hematology Disease Topics & Pathways:
Bleeding and Clotting, Diseases, Treatment Considerations, Biological therapies, Transplantation (Allogeneic and Autologous)
Saturday, December 7, 2024: 2:00 PM-3:15 PM
Room 24 (San Diego Convention Center)

Description:
The American Society of Hematology educational session will delve into the complexities of thrombotic microangiopathies (TMAs) outside the typical presentation of thrombotic thrombocytopenic purpura (TTP).

The session will address three related disease states: Transplant-Associated Thrombotic Microangiopathy (TA-TMA), atypical Hemolytic Uremic Syndrome (aHUS) and Catastrophic Antiphospholipid Antibody Syndrome (CAPs).

The segment on TA-TMA will cover its incidence in the post-transplant period, the challenges of distinguishing TA-TMA from other post-transplant complications, and the data on emerging treatment approaches. The session will also include a comprehensive review of aHUS, focusing on its genetic underpinnings, atypical presentations, and the latest advancements in targeted therapies, such as complement inhibitors. The discussion will encapsulate the nuances of managing these atypical TMAs, highlighting case studies and clinical trials that underscore the critical role of personalized medicine in improving patient outcomes. This session will also explore Catastrophic Antiphospholipid Syndrome (CAPS), a rare and severe subtype of antiphospholipid syndrome characterized by widespread microvascular thrombi, leading to multiple organ failure. The talk will provide an overview of the pathophysiology, diagnostic criteria, and emerging treatment strategies. Discussion will also focus on distinguishing CAPS from other TMAs through clinical presentation and laboratory findings, emphasizing the importance of timely and accurate diagnosis to mitigate the high mortality rate associated with this condition.

Chair:
Mark Crowther, MS MSc LLM FRCPC FRSC, McMaster University
Disclosures:
Crowther: Bayer: Membership on an entity's Board of Directors or advisory committees; Eversana: Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Speakers Bureau; Pfizer: Speakers Bureau.
The American Society of Hematology educational session will delve into the complexities of thrombotic microangiopathies (TMAs) outside the typical presentation of thrombotic thrombocytopenic purpura (TTP).

The session will address three related disease states: Transplant-Associated Thrombotic Microangiopathy (TA-TMA), atypical Hemolytic Uremic Syndrome (aHUS) and Catastrophic Antiphospholipid Antibody Syndrome (CAPs).

The segment on TA-TMA will cover its incidence in the post-transplant period, the challenges of distinguishing TA-TMA from other post-transplant complications, and the data on emerging treatment approaches. The session will also include a comprehensive review of aHUS, focusing on its genetic underpinnings, atypical presentations, and the latest advancements in targeted therapies, such as complement inhibitors. The discussion will encapsulate the nuances of managing these atypical TMAs, highlighting case studies and clinical trials that underscore the critical role of personalized medicine in improving patient outcomes. This session will also explore Catastrophic Antiphospholipid Syndrome (CAPS), a rare and severe subtype of antiphospholipid syndrome characterized by widespread microvascular thrombi, leading to multiple organ failure. The talk will provide an overview of the pathophysiology, diagnostic criteria, and emerging treatment strategies. Discussion will also focus on distinguishing CAPS from other TMAs through clinical presentation and laboratory findings, emphasizing the importance of timely and accurate diagnosis to mitigate the high mortality rate associated with this condition.

Anuja Java

Washington University in St. Louis, St. Louis, MO

Ang Li, MD, MS

Baylor College of Medicine, Houston, TX

Mark Crowther, MS MSc LLM FRCPC FRSC

Department of Medicine, McMaster University, Hamilton, ON, Canada

See more of: Education Program